BioCryst Pharma Analyst Ratings
BioCryst Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/25/2023 | 34.41% | RBC Capital | → $10 | Reiterates | Outperform → Outperform |
| 09/18/2023 | 34.41% | RBC Capital | $9 → $10 | Upgrades | Sector Perform → Outperform |
| 08/04/2023 | 20.97% | RBC Capital | $8 → $9 | Maintains | Sector Perform |
| 08/04/2023 | 47.85% | Jefferies | → $11 | Upgrades | Hold → Buy |
| 08/04/2023 | 303.23% | HC Wainwright & Co. | → $30 | Reiterates | Buy → Buy |
| 08/03/2023 | 61.29% | Needham | $14 → $12 | Reiterates | → Buy |
| 07/13/2023 | 34.41% | B of A Securities | → $10 | Upgrades | Neutral → Buy |
| 05/04/2023 | 20.97% | RBC Capital | → $9 | Reiterates | → Sector Perform |
| 05/04/2023 | 88.17% | Needham | → $14 | Reiterates | → Buy |
| 04/20/2023 | 34.41% | Evercore ISI Group | $13 → $10 | Maintains | Outperform |
| 04/20/2023 | 88.17% | Needham | → $14 | Reiterates | → Buy |
| 03/14/2023 | 34.41% | RBC Capital | → $10 | Reiterates | → Sector Perform |
| 02/22/2023 | 115.05% | JMP Securities | → $16 | Reiterates | → Market Outperform |
| 02/22/2023 | 88.17% | Needham | → $14 | Upgrades | Hold → Buy |
| 02/22/2023 | 303.23% | HC Wainwright & Co. | → $30 | Reiterates | → Buy |
| 11/02/2022 | 115.05% | Evercore ISI Group | → $16 | Upgrades | In-Line → Outperform |
| 11/02/2022 | 74.73% | RBC Capital | $14 → $13 | Maintains | Sector Perform |
| 08/08/2022 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 08/05/2022 | 88.17% | Barclays | $12 → $14 | Maintains | Equal-Weight |
| 08/05/2022 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 08/05/2022 | 88.17% | Evercore ISI Group | → $14 | Downgrades | Outperform → In-Line |
| 04/18/2022 | 74.73% | Barclays | $22 → $13 | Downgrades | Overweight → Equal-Weight |
| 04/12/2022 | 88.17% | RBC Capital | $16 → $14 | Maintains | Sector Perform |
| 04/11/2022 | 88.17% | B of A Securities | → $14 | Downgrades | Buy → Neutral |
| 04/11/2022 | 115.05% | Oppenheimer | $20 → $16 | Maintains | Outperform |
| 12/10/2021 | 115.05% | Oppenheimer | → $16 | Initiates Coverage On | → Outperform |
| 11/04/2021 | 88.17% | RBC Capital | $16 → $14 | Maintains | Sector Perform |
| 11/04/2021 | 128.49% | Barclays | $21 → $17 | Maintains | Overweight |
| 08/06/2021 | 209.14% | JMP Securities | $22 → $23 | Maintains | Market Outperform |
| 08/06/2021 | — | Jefferies | Downgrades | Buy → Hold | |
| 08/06/2021 | 115.05% | RBC Capital | $13 → $16 | Maintains | Sector Perform |
| 08/06/2021 | 182.26% | Barclays | $20 → $21 | Maintains | Overweight |
| 08/06/2021 | 303.23% | HC Wainwright & Co. | $18 → $30 | Maintains | Buy |
| 08/03/2021 | 182.26% | Cantor Fitzgerald | → $21 | Initiates Coverage On | → Overweight |
| 03/24/2021 | 155.38% | HC Wainwright & Co. | $14 → $19 | Maintains | Buy |
| 01/22/2021 | 20.97% | RBC Capital | $7 → $9 | Maintains | Sector Perform |
| 12/07/2020 | 88.17% | HC Wainwright & Co. | $13 → $14 | Maintains | Buy |
| 11/24/2020 | 61.29% | Evercore ISI Group | → $12 | Initiates Coverage On | → Outperform |
| 06/17/2020 | — | BTIG | Initiates Coverage On | → Neutral | |
| 05/05/2020 | -5.91% | Barclays | $4 → $7 | Upgrades | Equal-Weight → Overweight |
| 11/15/2019 | — | B of A Securities | Upgrades | Neutral → Buy | |
| 05/24/2019 | -39.52% | RBC Capital | $16 → $4.5 | Downgrades | Outperform → Sector Perform |
| 04/02/2019 | 7.53% | Barclays | $6 → $8 | Maintains | Equal-Weight |
| 04/02/2019 | 141.94% | JMP Securities | $16 → $18 | Maintains | Market Outperform |
| 11/16/2018 | 101.61% | Piper Sandler | → $15 | Reinstates | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 09/25/2023 | 34.41% | 加拿大皇家銀行資本 | →$10 | 重申 | 跑贏→跑贏大盤 |
| 09/18/2023 | 34.41% | 加拿大皇家銀行資本 | $9→$10 | 升級 | 行業表現優於→ |
| 08/04/2023 | 20.97% | 加拿大皇家銀行資本 | $8→$9 | 維護 | 行業表現 |
| 08/04/2023 | 47.85% | 傑富瑞 | →$11 | 升級 | 持有→購買 |
| 08/04/2023 | 303.23% | HC Wainwright公司 | →$30 | 重申 | 購買→購買 |
| 08/03/2023 | 61.29% | 李約瑟 | $14→$12 | 重申 | →購買 |
| 07/13/2023 | 34.41% | B of A證券 | →$10 | 升級 | 中性→購買 |
| 05/04/2023 | 20.97% | 加拿大皇家銀行資本 | →$9 | 重申 | →行業表現 |
| 05/04/2023 | 88.17% | 李約瑟 | →$14 | 重申 | →購買 |
| 04/20/2023 | 34.41% | Evercore ISI集團 | $13→$10 | 維護 | 跑贏大盤 |
| 04/20/2023 | 88.17% | 李約瑟 | →$14 | 重申 | →購買 |
| 03/14/2023 | 34.41% | 加拿大皇家銀行資本 | →$10 | 重申 | →行業表現 |
| 02/22/2023 | 115.05% | JMP證券 | →$16 | 重申 | →市場跑贏大盤 |
| 02/22/2023 | 88.17% | 李約瑟 | →$14 | 升級 | 持有→購買 |
| 02/22/2023 | 303.23% | HC Wainwright公司 | →$30 | 重申 | →購買 |
| 11/02/2022 | 115.05% | Evercore ISI集團 | →$16 | 升級 | 線內→表現優異 |
| 11/02/2022 | 74.73% | 加拿大皇家銀行資本 | $14→$13 | 維護 | 行業表現 |
| 2022/08/08 | - | 奧本海默 | 評級下調 | 超越→表現 | |
| 08/05/2022 | 88.17% | 巴克萊 | $12→$14 | 維護 | 等重 |
| 08/05/2022 | - | 奧本海默 | 評級下調 | 超越→表現 | |
| 08/05/2022 | 88.17% | Evercore ISI集團 | →$14 | 評級下調 | 勝過→同線 |
| 04/18/2022 | 74.73% | 巴克萊 | $22→$13 | 評級下調 | 超重→等重 |
| 04/12/2022 | 88.17% | 加拿大皇家銀行資本 | $16→$14 | 維護 | 行業表現 |
| 04/11/2022 | 88.17% | B of A證券 | →$14 | 評級下調 | 購買→中性 |
| 04/11/2022 | 115.05% | 奧本海默 | $20→$16 | 維護 | 跑贏大盤 |
| 2021年12月10日 | 115.05% | 奧本海默 | →$16 | 開始承保 | →跑贏大盤 |
| 11/04/2021 | 88.17% | 加拿大皇家銀行資本 | $16→$14 | 維護 | 行業表現 |
| 11/04/2021 | 128.49% | 巴克萊 | $21→$17 | 維護 | 超重 |
| 08/06/2021 | 209.14% | JMP證券 | $22→$23 | 維護 | 市場表現強於大盤 |
| 08/06/2021 | - | 傑富瑞 | 評級下調 | 購買→Hold | |
| 08/06/2021 | 115.05% | 加拿大皇家銀行資本 | $13→$16 | 維護 | 行業表現 |
| 08/06/2021 | 182.26% | 巴克萊 | $20→$21 | 維護 | 超重 |
| 08/06/2021 | 303.23% | HC Wainwright公司 | $18→$30 | 維護 | 買 |
| 08/03/2021 | 182.26% | 康託·菲茨傑拉德 | →$21 | 開始承保 | →超重 |
| 03/24/2021 | 155.38% | HC Wainwright公司 | $14→$19 | 維護 | 買 |
| 2021/01/22 | 20.97% | 加拿大皇家銀行資本 | $7→$9 | 維護 | 行業表現 |
| 12/07/2020 | 88.17% | HC Wainwright公司 | $13→$14 | 維護 | 買 |
| 11/24/2020 | 61.29% | Evercore ISI集團 | →$12 | 開始承保 | →跑贏大盤 |
| 06/17/2020 | - | BTIG | 開始承保 | →中性 | |
| 05/05/2020 | -5.91% | 巴克萊 | $4→$7 | 升級 | 等重→超重 |
| 2019年11月15日 | - | B of A證券 | 升級 | 中性→購買 | |
| 2019年05月24日 | -39.52% | 加拿大皇家銀行資本 | $16→$4.5 | 評級下調 | 跑贏→板塊表現 |
| 2019年02月04日 | 7.53% | 巴克萊 | $6→$8 | 維護 | 等重 |
| 2019年02月04日 | 141.94% | JMP證券 | $16→$18 | 維護 | 市場表現強於大盤 |
| 2018年11月16日 | 101.61% | 派珀·桑德勒 | →$15 | 恢復 | →超重 |
What is the target price for BioCryst Pharma (BCRX)?
BioCryst Pharma(BCRX)的目標價格是多少？
The latest price target for BioCryst Pharma (NASDAQ: BCRX) was reported by RBC Capital on September 25, 2023. The analyst firm set a price target for $10.00 expecting BCRX to rise to within 12 months (a possible 34.41% upside). 17 analyst firms have reported ratings in the last year.
加拿大皇家銀行資本於2023年9月25日報道了BioCryst Pharma(納斯達克：BCRX)的最新目標價。這家分析公司將目標價定為10.00美元，預計BCRX將在12個月內上漲(可能上漲34.41%)。過去一年，17家分析公司公佈了評級。
What is the most recent analyst rating for BioCryst Pharma (BCRX)?
BioCryst Pharma(BCRX)的最新分析師評級是什麼？
The latest analyst rating for BioCryst Pharma (NASDAQ: BCRX) was provided by RBC Capital, and BioCryst Pharma reiterated their outperform rating.
生物冷凍製藥(納斯達克：BCRX)的最新分析師評級由加拿大皇家銀行資本提供，BioCryst Pharma重申其表現優於大盤的評級。
When is the next analyst rating going to be posted or updated for BioCryst Pharma (BCRX)?
BioCryst Pharma(BCRX)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioCryst Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioCryst Pharma was filed on September 25, 2023 so you should expect the next rating to be made available sometime around September 25, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與BioCryst Pharma的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。BioCryst Pharma的上一次評級是在2023年9月25日提交的，所以你應該預計下一次評級將在2024年9月25日左右的某個時候提供。
Is the Analyst Rating BioCryst Pharma (BCRX) correct?
分析師對BioCryst Pharma(BCRX)的評級正確嗎？
While ratings are subjective and will change, the latest BioCryst Pharma (BCRX) rating was a reiterated with a price target of $0.00 to $10.00. The current price BioCryst Pharma (BCRX) is trading at is $7.44, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的BioCryst Pharma(BCRX)評級被重申，目標價在0.00美元至10.00美元之間。BioCryst Pharma(BCRX)目前的交易價格為7.44美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。